source
- Beam Therapeutics reports successful pivotal trial of base editing sickle cell therapyBeam Therapeutics announced that its base editing treatment, ristoglogene autogetemcel (risto‑cel), met its primary goal in a pivotal trial for sickle cell disease. The trial showed the therapy cou…
- Ionis shares tumble over $1 billion as Tryngolza sales forecast cut in halfIonis Pharmaceuticals saw its market value drop by more than $1 billion after it lowered its sales outlook for Tryngolza, a triglyceride‑lowering therapy. The company now expects $50 million in sa…